SCIENCE & TECHNOLOGY BEHIND COMED HOOKS
COMED Introduces a First-in-Class Intracellular Delivery Platform
We developed a method for biologically guided intracellular delivery, and engineered therapeutic cargos for targeted therapy—together forming a scientifically unprecedented platform.
Mechanism of Action
COMED Hooks are engineered antibody-based constructs designed to tether onto the body's own transport systems—turning a natural, endogenous biological pathway into a delivery route across the cell membrane.
Once inside, COMED Hooks carry antibodies, proteins, peptides, enzymes, or nucleic acids such as mRNA directly into the cytoplasm, enabling functional engagement with intracellular targets.
One Platform,
Two Engineered Systems
Uniform delivery logic. Different cargo. That's what makes COMED Hooks a versatile platform, not a single therapeutic.
A common biology-guided delivery mechanism engineered into two complementary therapeutic modalities:
Protein Targeting
Engineered to deliver antibody-based therapeutics into cells, enabling selective modulation of disease-driving intracellular proteins that remain inaccessible to conventional biologics.
Nucleic Acid Delivery
Engineered to transport RNA therapeutics, including mRNA and siRNA, using the same biology-guided delivery principle to enable intracellular release and therapeutic activity.
Where Synthetic Delivery Systems Struggle, Biology Delivers
First-in-Class Intracellular Access
Reaches disease-driving intracellular targets beyond the reach of conventional biologics which are largely confined to extracellular or surface-level engagement.
Multiple Modalities, Unified Architecture
A single biology-guided delivery mechanism engineered for antibodies, proteins, peptides, enzymes and RNA therapeutics.
Physiological Cellular Entry
Repurposes one of the body's endogenous cellular transport systems instead of relying on synthetic lipid or polymer carriers.
Functional Cytosolic Delivery
Designed to achieve productive cytosolic availability rather than endosomal sequestration.
Engineered for Manufacturability & Scalability
Built for clean, predictable, scalable production, addressing a common bottleneck for more complex synthetic delivery platforms.
Low Immunogenicity, Low Aggregation
A protein-engineered architecture designed to minimize aggregation and immune recognition.
Potential Blood–Brain Barrier Applications
Designed with the potential to reach CNS tissue, an application where most delivery systems face substantial restriction.
Broad Therapeutic Applicability
Adaptable across oncology, genetic medicine, infectious disease and RNA therapeutics.
Proof of Intracellular Delivery
COMED Hooks platform has been validated using complementary orthogonal methods demonstrating efficient, reproducible and active intracellular internalization across multiple pancreatic cancer cell models.
Live-cell Imaging
Real-time visualization confirmed active intracellular internalization at the single-cell level.
Images acquired at sequential time points from PANC1 cell lines following COMED Hooks exposure show a progressive increase in intracellular fluorescence puncta over time, consistent with active and sustained cellular internalization.
Flow Cytometry
Quantitative analysis demonstrated efficient and sustained intracellular uptake across multiple cell models.
Representative histograms of internalization of dye-conjugated antibodies by CAPAN2, MIAPACA2, PANC1 cells at the concentration of 40 µg/mL
X-axis: Fluorescence intensity. Y-axis: Event count. Red: Cells incubated without dye-conjugated antibody. Blue: Cells incubated with dye-conjugated antibody.
Shift in fluorescence indicates internalization of the dye-conjugated compound.
Together, these complementary methods confirm that the platform functions as designed and provides the foundation for downstream therapeutic applications.
Additional evidence, including target-specific binding data and in vivo study results further validates this mechanism within our oncology program.
Translating COMED Hooks Platform into Programs
Oncology
Enabling intracellular antibody-mediated inhibition of mutant and disease-driving proteins.
Infectious Diseases
Enabling intracellular antibody therapeutics to target pathogen-derived proteins within infected cells, particularly in intracellular parasitic diseases.
Genetic Diseases
Delivering next-generation RNA therapeutics to restore cellular homeostasis and protein function without genome modification.